NASDAQ: FENC FENNEC PHARMACEUTICALS INC. 10-Q

Fennec turns profitable on 73% revenue growth; Cipla settlement extends exclusivity to 2033

Filed May 14, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade FENC commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov

Generated by AI · May 27, 2026 1:38 AM